![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways. The Company has recently licensed two drug candidates, MLR-1019 and MLR-1023, from the Melior Discovery family of companies. Adhe... Adhera Therapeutics is a clinical stage biopharmaceutical company focused on identifying advanced drug candidates that may qualify for accelerated developmental pathways. The Company has recently licensed two drug candidates, MLR-1019 and MLR-1023, from the Melior Discovery family of companies. Adhera is developing MLR-1023 (tolimidone) as a new drug for Type I diabetes with a focus on C-peptide positive patients. MLR-1023, a lyn kinase activator, has demonstrated exceptional clinical safety and tolerability in over 700 patients in Phase 2a and Phase 2b Type 2 diabetes studies. MLR-1019 (armesocarb) is a new class of drug for Parkinson's Disease (PD) and represents the only drug to address both movement and non-movement symptoms of PD. Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications. In addition to advancing both drug candidates in Phase 2 clinical trials, the Company remains active in exploring other advanced drug development opportunities while maintaining its legacy assets, including CEQ508, an oral delivery of small interfering RNA (siRNA) against beta-catenin, to suppress polyps in the precancerous syndrome and orphan indication Familial Adenomatous Polyposis (FAP). Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.0004 | 5 | 0.008 | 0.0085 | 0.008 | 18463 | 0.00817177 | CS |
4 | 0.00235 | 38.8429752066 | 0.00605 | 0.017 | 0.0031 | 39497 | 0.0126502 | CS |
12 | -0.0005 | -5.61797752809 | 0.0089 | 0.017 | 0.0011 | 45153 | 0.00734994 | CS |
26 | -0.0166 | -66.4 | 0.025 | 0.025 | 0.0011 | 88346 | 0.01219844 | CS |
52 | -0.03635 | -81.2290502793 | 0.04475 | 0.06 | 0.0011 | 138607 | 0.01589394 | CS |
156 | -0.0706 | -89.3670886076 | 0.079 | 1.09 | 0.0011 | 124353 | 0.11641114 | CS |
260 | -0.1516 | -94.75 | 0.16 | 1.09 | 0.0011 | 84909 | 0.11321483 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions